Can Sotagliflozin Prevent Cardiovascular Ailments for Patients with Diabetes and Chronic Kidney Disease Cardiovascular diseases, including stroke, are major healthcare issues affecting humans worldwide. Between 2010 and 2030, the estimated total medical costs might escalate to from $273–$818 billion in the United States alone. Modifiable risk factors for stroke include hypertension, diabetes,
Involvement of Ocular Surface in Graft‐Versus‐Host Disease: A Review
Involvement of Ocular Surface in Graft-Versus-Host Disease: A Review Hematopoietic stem cell transplantation (HSCT) is a promising curative therapy for hematologic malignancies and other disorders of blood and bone marrow. Historically, HSCT was referred to as bone marrow transplantation (BMT) because bone marrow was the sole source of transplanted hematopoietic stem
Using Ultrasound to Analyze Malignant and Benign Orbital Space-Occupying Lesions
Using Ultrasound to Analyze Malignant and Benign Orbital Space-Occupying Lesions Most orbital space-occupying lesions come from tissues in the orbital space or metastasize from other system tumors. The bulk of clinical manifestations of these lesions such as diplopia, protrusion, and loss of vision are often nonspecific, so imaging technology is crucial
Risk Factors for Ocular Metastases in Invasive Ductal Carcinoma
Risk Factors for Ocular Metastases in Invasive Ductal Carcinoma Invasive ductal carcinoma (IDC), also known as infiltrating ductal carcinoma, is the most common type of breast cancer, accounting for about 72% of all cases. IDC can occur at any age, but many people are over the age of 55 at the
Myelofibrosis – Biology, Management, and Case Report of Ocular Manifestation
MF-BIOLOGY, MANAGEMENT, AND CASE REPORT OF OCULAR MANIFESTATION Myelofibrosis is an uncommon myeloproliferative neoplasm, a type of blood cancer where excess red blood cells, white blood cells, or platelets are produced in the bone marrow. The rarity of this abnormality has many medical professionals struggling to understand its genetic underpinnings. This
Malignancy in Myelofibrosis Patients Receiving Ruxolitinib Therapy
A Restrospective Study of Secondary Malignancies in Myelofibrosis Patients Receiving Ruxolitinib Therapy Myelofibrosis (MF) is a chronic, rare, and often fatal type of blood cancer characterized by a progressive replacement of bone marrow with fibrous scar tissue. This type of myeloproliferative neoplasm (MPN) leads to progressive spleen enlargement, systemic symptoms such
Study on the Ocular involvement in metastatic and systemic malignancies
Ocular Involvement of Systemic Malignancies Systemic malignancies affecting the eye often involve the choroid or the orbital area of the eye, leading to different ocular manifestations. Ocular malignancies are relatively rare compared to malignancies of other parts of the human body. The American Cancer Society estimates there will be about 3,300 new eye cancer
Genetic Mutations for Predicting Pancreatic Ductal Adenocarcinoma Susceptibility
Genetic Mutations for Predicting Pancreatic Ductal Adenocarcinoma Susceptibility Pancreatic ductal adenocarcinoma (PDAC) is the deadliest malignancy representing about 90% of all pancreatic cancers. PDAC progresses asymptomatically until death and is refractory to most treatment methods. Surgery is the most effective treatment. Nevertheless, it is well known that only 15-20% of PDAC
Using Nanofiber Antibiotic Sutures Prevent Ophthalmic Infections
Using Nanofiber Antibiotic Sutures to Prevent Ophthalmic Infections Sutures are medical devices applied on the site of injury or surgery. Sutures prevent infection, minimize scarring, and fasten recovery. As of today, the only drug-eluting sutures available for antibacterial application in most surgeries are coated with >triclosan. It’s known that putting drugs
Exploring Gene Profiles in Small Bowel Adenocarcinoma
Exploring Gene Profiles in Small Bowel Adenocarcinoma Small bowel adenocarcinoma (SBA) is one of the rarest tumors found in patients. In fact, SBA only represents about 1-3% of all gastrointestinal malignancies. Due to its rarity, genomic analyses and prognostic biomarkers are limited. About 55-82% of small bowel adenocarcinomas can be found in
